By bridging NK cells to tumor-associated antigens (TAAs) such as HER2, CD19, or BCMA, NKCEs enhance NK cell-mediated cytotoxicity through the activation of receptors like CD16 (FcγRIII), NKG2D, or NKp30 (Figure 4). This evidence concerns the gene ERBB2 and neoplasm.